Research and Practice in Thrombosis and Haemostasis

Article	Citations
Navigating the inevitable: artificial intelligence and the future of scientific communication	87
Intraindividual variability of von Willebrand factor and the need for repeated testing	66
Promise and pitfalls of viscoelastic testing for assessing blood hemostasis in ultraendurance sports	62
Contemporary trends in maternal outcomes during delivery hospitalizations among pregnancies complicated by von Willebrand disease—a cross-sectional analysis	59
Acquired von Willebrand syndrome in children	51
Reevaluating thromboprophylaxis in COVID-19 outpatients: the case for a targeted, risk-based approach	50
Corrigendum to ‘Optimizing care for patients after major anticoagulant-related bleeding: a narrative review and proposal for a clinical care pathway’	44
Effect of DNA methylation on inhibitor development in people with hemophilia A treated with FVIII concentrates	43
Impact of antiplatelet therapy on hemostatic plug formation in the setting of thrombocytopenia	40
Exploration of biomarkers for inhibitor development in persons with hemophilia A	40
Accumulating evidence for direct oral anticoagulants in liver disease	38
PB0299 Surface Modification of Lung Assist Device for Neonates by Dual-Modification with Antithrombin-Heparin (ATH) and Tissue Plasminogen Activator (t-PA)	37
PB0403 A Common Variant in GRK5 Reveals a PAR1-Specific Regulation in Platelets	36
PB1140 Laboratory Features and Genotype of a Family with Heritable Dysfibrinogenaemia (HD)	36
PB0074 Hyper-Immunoglobulin-CovImmuneTM, Provides a Broader Coverage Against Diverse SARS-CoV-2 Variants Relevant to the COVID-19 Pandemic	34
PB0186 Results from BeneGene-1 Study: Prospective Collection of Bleeding Rate in Hemophilia B Patients Prior to Phase 3 Study (BeneGene-2) of Fidanacogene Elaparvovec	33
PB1463 Clinical Predictors of In-Hospital Mortality in Patients with Acute Pulmonary Embolism: 15-Years Experience in a Single Center in Argentina	31
PB1031 Assessment of Coagulation Factor Levels in LVAD Patients Following Temporary Warfarin Reversal with 4F-PCC: KVAD Study	29
PB1020 Simultaneous Generation of Thrombin and Plasmin in Patients with Deep Vein Thrombosis and High Levels of Lipoprotein (a)	28
OC 74.1 Circulating Biomarkers and Mortality in Atrial Fibrillation: The Reasons for Geographic and Racial Differences in Stroke Study	28
PB1228 Inhibitor Detection in Acquired Hemophilia A: A Comparison between the Nijmegen Modified Bethesda Assay and an Anti-FVIII ELISA	28
OC 45.3 Major Bleeding Event Rates in Patients on Hemodialysis and Peritoneal Dialysis: Results from the International DOPPS and PDOPPS	28
PB0386 Increased Platelet Expression of the Transcriptional Suppressor ETV6 Can Be Detected by Immunofluorescence on the Blood Smear and Associates with ETV6-Related Thrombocytopenia	28
PB0249 Some Coagulation Profiles (PT, APTT, TT, FIB), Red Cell, Total White Cell, Platelet Counts and Their Indices Activity Levels in Persons Exposed to Wood Smoke (Firewood) in Calabar, Nigeria	26
PB0308 Anticoagulation Monitoring of UFH (Unfractioned Heparin) in a Pediatric Patient during Long Term ECMO (Extracorporeal Membrane Oxygenation)	26

OC 14.2 Pharmacokinetic Characteristics of ADAMTS13 in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Interim Results from a Phase 3 Randomized, Controlled, Open-Label, Crossover Study	26
Erratum to ‘A comparative study in type 2 von Willebrand disease patients using four different platelet-dependent von Willebrand factor assays.’ [Research and Practice in Thrombosis and Haemostasis Vo	25
PB0796 Interferon Treatment Suppresses in vitro NETosis in Neutrophils Derived from Patients with Myeloproliferative Neoplasms	25
PB0612 COVID-19: Predictive Value of Methemoglobinemia	23
PB0926 Venous Thromboembolism and Risk of Depression in Patients with Hematological Cancer: A Population-Based Cohort Study	23
PB0715 H3 Alters the Behavior of Endothelial Cells In Vitro	23
PB0464 Smaller Nadroparin Dose Reductions Required for Patients with Renal Impairment: A Multicenter Study	23
PB1142 A Rapid Centrifugation 4000 g, 4 min Does not Impact Routine Coagulation Assays	22
OC 75.1 First US Rare Bleeding Disorder Genotype-Phenotype Registry (ATHN 10) Discovers Many Individuals with Both Novel and Multiple Variants using a Customized 30-Gene Next-Generation Sequencing Pan	22
OC 50.1 Levels of IgG4 Distinguish Immune Tolerance Induction Outcome in Patients with Inherited Hemophilia A: Results from the BrazIT Study	21
PB1060 Thrombin Generation and Fibrin Clot Structure in Nephrotic Patients with Primary Glomerular Disorders	21
PB0358 Hereditary Bleeding Disorders Web-Based Registry of Patients with Inherited Platelet Disorders	21
PB0679 Clinical Characteristics and Disease Outcomes in Previously Treated Patients with Haemophilia: Results from a Real-World Study in Europe and United States	21
Issue Information	21
PB0412 Simulating the Impact of Thrombin on Platelet Function Requires Simultaneous Activation of Both PAR-1 and PAR-4	21
PB0627 Management of Invasive Procedures in Patients with Hemophilia A Receiving Emicizumab Prophylaxis: Real-World Data from a National Hemophilia Treatment Center	21
OC 61.3 CS585 is a Novel and Highly Selective IP Receptor Agonist for Prevention of Thrombosis	20
PO04 SARS-CoV-2 Vaccinations and Risk of Venous Thrombosis - Case Control Study	20
PB1117 Congenital Thrombotic Thrombocytopenic Purpura: Identification of Two Heterozygous Mutations in Splice Sites through NGS Sequencing	20
PB0815 Involvement of the Nuclear Protein, TC2N, in Regulating VWF Levels in Endothelial Cells	20
PB1385 Developing a Stem Cell-Based Model for Glanzmann Thrombasthenia to Explore VWF-GPIb Axis during Megakaryopoeisis	19
OC 71.4 Management Patterns of Antithrombotics and Outcomes in Patients with Hematological Malignancy and Thrombocytopenia: A Prospective Registry (Matter Study)	19
OC 03.2 Characterization of Peripheral Monocyte Subsets in a Prospective Cohort of Patients with Acute Stroke Suspicion: Results of BOOST Study	19
OC 53.5 Clinical Outcomes in Patients with Acute Pulmonary Embolism Undergoing Ultrasound-Assisted Catheter-Directed Thrombolysis	19
OC 42.5 Hemorrhagic Risk of Caplacizumab in the Treatment of Thrombotic Thrombocytopenic Purpura a Pharmacovigilance Study from 2020–2022 FAERS Database	19
Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3	18
OC 71.5 Reasons for Anticoagulation Failure and Provider Management	18
PB0046 Increased Platelet Activation Demonstrated by Elevated CD36 and P-Selectin Expression in 1-year Post Recovered COVID-19 Patients	18
140 Impact of Amiodarone Exposure on Apixaban Pharmacokinetics in Hospitalized Patients	18
Communication at diagnosis of venous thromboembolism: Lasting impact of verbal and nonverbal provider communication on patients	18
PO16 Hemorrhagic Complications in Patients with Hemophilia A	18
Real-world usage and effectiveness of recombinant factor VIII/factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany	18
How to use and report data on D‐dimer testing in the COVID‐19 era?	18
PB0957 The Application of Existing Risk Assessment Models (RAMs) to Predict the Occurrence of Venous Thromboembolic Events among Patients with Classic Hodgkin's Lymphoma	18
84 Rural Improvements in Venous Thrombosis Treatment in Oklahoma: The RIVETT-OK Initiative	17
Real-world andexanet alfa utilization and the association between delay in administration due to hospital transfer and all-cause inpatient mortality	17
128 Evaluation of Heparin-Induced Thrombocytopenia Testing to Improve Anticoagulation Stewardship in an Acute Care Setting	17
141 Heparin Management - The Ultimate Goldilocks Dilemma: A Quality Improvement Project	17
Rare inherited coagulation disorders: no longer orphan and neglected	16
Von Willebrand disease diagnosis: from complexity to simplicity	16
Prognostic Value of the Pan-Immune-Inflammation Value for Mortality in Sepsis-Induced Coagulopathy: A MIMIC Study	16
Performance of risk scores in predicting major bleeding in left ventricular assist device recipients: a comparative external validation	16
Cryo‐EM structures of coagulation factors	16
Do combined oral contraceptives induce formation of tissue factor?	16
How do anticoagulants impact menstrual bleeding and quality of life? - The PERIOD study	15
Major bleeding and thromboembolism risks of antithrombotic treatment in patients with incident atrial fibrillation/flutter and a history of cancer	15
Blocking domain 6 of high molecular weight kininogen to understand intrinsic clotting mechanisms	15
Thrombo‐inflammatory biomarkers and D‐dimer in a biracial cohort study	15
Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China	15
Emicizumab prophylaxis in current haemophilia A care in the Czech Republic—data from the Czech National Haemophilia Programme Registry	15

Thrombophilia and outcomes of venous thromboembolism in older patients	15
Probing rare von Willebrand disease–causing mutations in the D4 and C-domains of von Willebrand factor	14
PB1193 Acute Myocardial Infarction Thrombi Show Fibrin Film that Increases with Ischaemia Duration	14
PB0706 Mechanism by which Coagulation Factor XI Regulates Endothelial Cell Permeability and Barrier Function In Vitro and In Vivo	14
Lower early mortality and risk prediction improvement of obesity after acute pulmonary embolism: results from a multicenter cohort analysis with external validation	14
Hematopoietic stem cell transplantation in a newborn suffering from severe combined immunodeficiency and severe hemophilia A: a case report and review of the literature	14
PB1427 Reduced ADAMTS13 Activity in Staphylococcus Aureus Bacteremia is Associated with Neutrophil-Mediated Citrullination	14
Editorial Board	14
PO19 Clinical Experiences in Managing the Transition to rIX-FP: Switching, Surgical Management and On-Demand	14
PB0979 Significantly Increased CVC Replacement in Patients with Both Symptomatic and Incidental Venous Thrombotic Events in Pediatric Cancer Patients: A Population-Based Study	14
PO26 Pulmonary Embolism in a Case with Thrombotic Thrombocytopenic Purpura after Plasmapheresis	13
PB0437 Concordance of Phosphatidylserine/Prothrombin and APhL Antibodies Associated with Antiphospholipid Syndrome-Associated Pregnancy Morbidity	13
PB0117 COVID-Associated Thrombosis: New Insights	13
PB1377 Living with Glanzmann's Thrombasthenia: An Interim Report from the Glanzmann's 360 International Patient Survey	13
D-dimer diagnostics: can I use any D-dimer assay? Bridging the knowledge-to-action gap	13
OC 11.1 Development and Validation of a Clinical Prediction Model for the Diagnostic Management of Acute Pulmonary Embolism: An Individual Participant Data Meta-Analysis	13
PB0448 Fibrin Clot Properties Identify Patients that Benefit from Catheter- Directed Thrombolysis: A Post Hoc Analysis of the CAVA Trial	13
PB1466 Early Mortality in Pulmonary Embolism - A Systematic Review and Analysis	13
PB1013 Evaluation of the Diagnostic Performance of Three D-Dimer Assays in Patients with Suspected Deep Vein Thrombosis	13
PB0695 Comparison of Platelet Quality and Hemostatic Function Across Apheresis Collection Platforms	13
PB0005 The Interest of the Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratio in the Prediction of Thrombus in Myocardial Infarction	13
PB0380 Corrections of Bernard Soulier Syndrome Megakaryocyte Phenotypes by Small Molecules and Interleukin-1α	13
PB1383 RUNX1-Mutated Familial Platelet Disorder (RUNX1-FPD) with Associated Acute Myeloid Leukaemia - A Case/Family Series	13
PB1210 Incorporation of a2-Plasmin Inhibitor into Plasma Clots of Patients with Venous Thrombosis	13
Bedside exclusion of pulmonary embolism in children without radiation (BEEPER): a national study of the Pediatric Emergency Care Applied Research Network—Study protocol	12
PB1519 Analysis of Aggregation Patterns Changes in Pregnant Women with Severe Preeclampsia	12
OC 72.5 Prediction of Venous Thromboembolism in Diverse Ancestry Populations Using Machine Learning and Electronic Health Records	12
PB1176 Analytical Performances Evaluation of the sthemO VWF:Ag Assay on the sthemO 301 Analyzer	12
Exploring heterogeneity in reported venous thromboembolism risk in COVID-19 and comparison to other viral pneumonias: a systematic review and meta-regression	12
Recurrence risk of venous thromboembolism associated with systemic lupus erythematosus: A retrospective cohort study	12
HTRS2023.P2.16 Prevalence of iron deficiency in patients with inherited bleeding disorders	12
OC 54.2 Comparison of Direct Oral Anticoagulants versus Low Molecular Weight Heparin in Primary and Metastatic Brain Cancers: A Meta-Analysis and Systematic Review	12
Advanced practice provider–led clinic for care transitions in newly diagnosed venous thromboembolism: establishment and utilization	12
OC 70.2 The First Insight into the Spatial Structure of Human Kininogen by Cryogenic Electron Microscopy and Computational Methods	12
HTRS2023.P2.3 F8 variants in women and girls evaluated for hemophilia A	12
SARS-CoV-2 vaccines are not associated with hypercoagulability in apparently healthy people	12
PB1133 DaXa, a Non-Calibrated Anti-FXa Assay that can be Used to Quantify DOAC Concentration in Acute Medical Emergencies	12
Galectin-3-binding protein and future venous thromboembolism	12
PB1072 A Novel Factor VIII Specific APC Resistance Assay	12
Stroke prevention in atrial fibrillation with chronic kidney disease: a delicate balance of efficacy and safety considerations	11
OC 22.1 Proteome and Phosphoproteome Analyses of SARS-CoV-2 Infected Humanized ACE2 Mice Platelets Revealed Reprogramming of Platelets from Early Hyperreactive to Late Antiviral Phenotypes	11
OC 60.1 Delineating VonWillebrand Factor Genetic Variants in Patients with a Von Willebrand Disease Diagnosis	11
Measuring ADAMTS-13 activity to diagnose thrombotic thrombocytopenic purpura: a novel, fast fiber-optic surface plasmon resonance immunoassay	11
PB0421 Phosphoproteomics and Systems Analysis Reveal Protein Kinase C Theta (PKCfɵ) Signaling Events Associated with the Generation of Procoagulant Platelets	11
PB0150 Fibrin Clot Formation is a Reliable Biological Marker to Evaluate FVIII Replacement Therapy in Hemophilia A Patients	11
Excluding pregnancy-associated deep vein thrombosis with whole-leg ultrasound	11
PB0723 Protease-Activated Receptor 4 Differentially Modulates TLR3- Dependent Responses In Vitro and In Vivo	11
PB0311 Anticoagulation in a Hypercoagulable Infant with End-Stage Renal Disease on Renal Replacement Therapies	11
PB1152 Reporting of DOAC Concentration as FXa Inhibitory Units - Potential Solution for Smaller Laboratories?	11
OC 75.3 Phenotype and Genotype Characterization of Patients with Congenital Fibrinogen Deficiencies: A Retrospective Analysis of the PRO-RBDD Database	11
Regulation of megakaryo/thrombopoiesis by endosomal toll-like receptor 7 and 8 activation of CD34+ cells in a viral infection model	11
PB1433 Opposing Effects of Canonical and Non-Canonical PAR-1 Activation in Experimental Diet-Induced Obesity and Fatty Liver Disease	11
Comparison of different algorithms for lupus anticoagulant detection: a single-center experience	11
PB1156 Clinical Performance Evaluation of the New Stago System for Fibrinogen and Thrombin Time Determination: sthemO Fib and sthemO Thrombin on sthemO 301 Analyzer	11
Measurement of factor XIII for the diagnosis and management of deficiencies: insights from a retrospective review of 10 years of data on consecutive samples and patients	10
Lupus anticoagulant associates with thrombosis in patients with COVID‐19 admitted to intensive care units: A retrospective cohort study	10
Thrombin generation and implications for hemophilia therapies: A narrative review	10
Neuraxial analgesia in pregnant individuals with bleeding disorders: a retrospective descriptive study of obstetric anesthesia practices and outcomes	10
Changes in body mass index following venous thromboembolism in children: a prospective cohort study	10
Extracellular vesicle tissue factor and tissue factor pathway inhibitor are independent discriminators of sepsis-induced coagulopathy	10
Joint health status in people with moderate hemophilia A: a cross-sectional multicenter study	10
OC 03.4 A Common, Racially Diverse Protease Activated Receptor 4 Functional Variant Impacts Ischemic Stroke Outcomes: Evidence for a Pharmacogenetic Effect	10
Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center	10
Thromboprophylaxis in multiple myeloma	10
Factor V variants in bleeding and thrombosis	10
Comparative safety of enoxaparin versus other low-molecular-weight heparins in cancer-associated venous thromboembolism: a real-world cohort study from RIETE	10
The diagnostic utility of genetic testing in inherited thrombocytopenia: regional multicenter tertiary experience	10
Effect of plasma levels of factor VIII according to procoagulant phospholipids on the risk of future venous thromboembolism	10
OC 77.1 Development, Validation, and Implementation of a Decision Support Tool for the Screening of Mild Bleeding Disorders	10
Interference of lupus anticoagulant causing antiprothrombin and anti–beta-2-glycoprotein I antibodies on international normalized ratio measurements: comparative analysis of international normalized r	10
Arthropathy on X-rays in 363 persons with hemophilia: long-term development, and impact of birth cohort and inhibitor status	10
Estimating incidence of venous thromboembolism in COVID‐19: Methodological considerations	10
132 Antithrombotic Prescribing Practices in Patients with Atrial Fibrillation Presenting with Acute Ischemic Stroke while on Oral Anticoagulation	10
Relevance of anti–platelet factor 4/heparin antibodies and platelet activation in systemic inflammatory diseases and thrombosis disorders: insight from the COVID-19 pandemic	10
Managing surgical relapse risk in acquired thrombotic thrombocytopenic purpura: a systematic review	10
Tissue factor-heparanase complex: intracellular nonhemostatic effects	10
PB1146 Comparison of Three Warfarin Monitoring Tests (PT, P&P and Fiix test) in Anticoagulated and Non-Anticoagulated Lupus Anticoagulant Positive Plasma Samples	10
PB0141 Characterizing the Transcriptomic Profile of Acquired Hemophilia Using RNA-Seq	9
Measurement of extended half-life recombinant FVIII molecules: In vitro and ex vivo evidence of relevant assay discrepancies	9
OC 60.5 Response to Desmopressin in Type 2N Von Willebrand’s Disease: A Genotype-Phenotype Analysis on a Cohort of 121 Patients	9

PB1424 PCF11 is a Central Hub in the Regulation of Inflammation in an Animal Model of Septicemia	9
PO08 Factor XIII Deficiency as Underlying Cause of Unexplained Intracranial Hemorrhage	9
PB0452 Glycemic Control and Plasma Levels of Pro-Inflammatory and Pro- Thrombotic Biomarkers in Diabetic Patients Presenting with Acute Pulmonary Embolism	9
PB1345 Health-Related Quality of Life Assessed by the SF-36 Health Survey in the Vienna ITP Biobank	9
PB0233 Von Willebrand Disease in the East Mediterranean Region: Current Situation and Gaps	9
PB0659 Patients with Hemophilia A have Increased Levels of Circulating Activated Protein C: Potential Contribution to their Hemostatic Status	9
Incidence rate of venous thrombosis in women switching combined oral contraceptives: a cohort study	9
PB1527 Sticky Platelet Syndrome and Pregnancy Complications - 18 Years' Experience in National Center of Hemostasis and Thrombosis in Slovak Republic	9
PB0708 The Tissue Factor/Thrombin Axis Limits Spontaneous Lymphatic Metastasis in Mice	9
PB0911 Platelet Reactivity in Patients with Atrial Fibrillation and Coronary Artery Disease under IIa Antagonists and Xa Antagonists	9
PB0319 Overexpression of ANKRD26 Results in Thrombocytopenia That May Exacerbate Clinical Phenotypes of Thrombotic Thrombocytopenic Purpura	9
PB0865 Endothelial Extracellular Vesicles Regulate In Situ Pulmonary Thrombosis in Sickle Cell Disease	9
PB0127 D-Dimer: Advantage Lost in the Post COVID Era?!	9
OC 27.2 Mechanistic Studies of Runt-Related Transcription Factor-1 (RUNX1)-Deficient Megakaryopoiesis and its Correction by RepSox (RS), a TGFβ-Receptor-1 Inhibitor	9
PB1517 Effect of Uteroplacental Manipulation on Hemostatic Markers during Cesarean Delivery and Hysterectomy for Placenta Accreta Spectrum	9
OC 35.3 Correlation between ETP-Based APC Resistance and the Relative Risk of Venous Thromboembolism in Women Using Combined Oral Contraceptives	9
PO34 The Risk of Vein Thromboembolism and Prevention in the Critically Illness Facilitated with an Electronic Decision Support System	9
OC 63.3 Combined Effect of High Factor VIII Levels and High Mean Platelet Volume on the Risk of Future Venous Thromboembolism	9
PB1062 Exogenous Warfarin Intoxication Associated with Munchaüsen Syndrome	9
Hereditary thrombotic thrombocytopenic purpura and COVID‐19: Impacts of vaccination and infection inrare disease	9
PB0315 Characterizing Protease-Resistant ADAMTS13 Mutants	9
PB0994 Intronic Exploration of PROC in Patients with Unexplained Protein C Deficiencies	9
PB0945 Effect of Drug Interactions with Apixaban on Clinical Outcomes in Cancer Patients with Venous Thromboembolism	9
PB0644 Evaluation of the Burden of Bone Fractures in People Living with Hemophilia: A Registry-Based Case-Control Study	9
PB1461 Peri-Operative Venous Thromboembolism (VTE) Risk for Below Knee Amputations	9
OC 38.3 Effects of Apixaban Versus No Anticoagulation on Biomarkers of Thrombin Generation in Pediatric Acute Lymphoblastic Leukemia (ALL): A Biomarker Sub-Study of PREVAPIX-ALL, a Randomized Controll	9
PB0837 Analysis of the Change in Diagnosis of von Willebrand Disease by Region and Economic Status	9
Aspirin nonsensitivity in patients with vascular disease: Assessment by light transmission aggregometry (aspirin nonsensitivity in vascular patients)	8
PB1263 Third Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol in Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World HEM-POWR Stud	8
Blood loss after coronary artery bypass by aspirin responsiveness assessed with preoperative VerifyNow aspirin testing	8
Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes	8
Response to: “Are women equal? Considering impact of therapeutic abortion bans on science”	8
PB0908 Therapeutic Efficacy of Platelet-Rich Plasma in Chronic Compression of the Dorsal Root Ganglion in Rat	8
OC 42.2 Incidence and Risk Factors of Major Adverse Cardiovascular Events in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura during Remission	8
Treatment of immune thrombocytopenia in Australian adults: A multicenter retrospective observational study	8
PB0707 Neutrophil Extracellular Traps Promote Cancer-Associated Inflammation and Myocardial Stress	8
PB1520 Deep Learning Extracts Embedded Signatures Associated with Pregnancy and Preeclampsia from Circulating Vesicle Profiles	8
OC 10.3 Platelets Mediate Intracranial Aneurysm Formation and Rupture in Mice	8
Issue Information	8
Patients with metabolic dysfunction–associated steatotic liver disease have preserved in vitro responses to antiplatelet drugs	8
Early SARS-CoV-2 infection: Platelet-neutrophil complexes and platelet function	8
PB0153 Evaluation of Cell Type-Specificity of Native Enhancer Elements from the F8 Locus	8
PB0633 Understanding the Requirement for Additional Factor VIII Infusion Associated with Novel Haemophilia A Treatments: An Expert Elicitation Exercise	8
PB0047 COVID-19 Infection-Associated Platelet and Neutrophil Activation is Blunted by Previous Anti-SARS-CoV-2 Vaccination	8
LB 01.4 Rare Germline Loss of Function Variants in SERPINH1 (HSP47) are Associated with Increased Risk of Thrombosis	8
PB1027 Delayed Diagnosis and Treatment of Deep Vein Thrombosis-an Underrecognized Factor for Its Related Complications?	8
PB0545 The Effect of a History of Preeclampsia on Hemostatic Balance in the Non-Pregnant State	8
PB1059 Single Amino Acid Substitutions of an Antibody Specific for a Non-Active Site of Activated Protein C (APC) Yielded an Antibody Library Capable of Modulating and Uncoupling APC Pleiotropic Funct	8
Platelet caspase‐1 and Bruton tyrosine kinase activation in patients with COVID‐19 is associated with disease severity and reversed in vitro by ibrutinib	8
HTRS2023.P4.20 Systematic review of global hemostasis assays in myeloproliferative neoplasms: promising tools for biomarkers for hypercoagulability	8
Underrepresentation and undertreatment of women in hematology: An unsolved issue	8
Epidemiology, treatment patterns, clinical outcomes, and disease burden among patients with immune‐mediated thrombotic thrombocytopenic purpura in the United States	8
HTRS2023.O8B.3 Elucidating the molecular mechanism of excessive phosphatidylserine exposure in sickle red cells	8
PB0408 Regulation of Collagen Binding Integrins by Alpha 7 and C Helix	8
PB0518 Novel Insights into Antifibrinolytic and Prothrombotic Functions of Lipoprotein(a)	8
PB1161 Evaluation of Three Prothrombin Time Reagents and their Sensitivity to Extrinsic Pathway Factor Deficiencies (FII, FV and FVII)	8
PB0628 The World Federation of Hemophilia Living Guidelines Model	7
PB0798 Role of Platelets in Maintain Lung Hemostasis during dsRNA-Induced Acute Respiratory Distress Syndrome (ARDS) in Mice	7
Mitral regurgitation is associated with similar loss of von Willebrand factor large multimers but lower frequency of anemia compared with aortic stenosis	7
The Evolution of Hemophilia Therapeutics: An Illustrated Review	7
166 The Value of Point-of-Care Ultrasound in Warfarin-Associated Spontaneous Hemothorax in late postoperative cardiac surgery	7
How I respond to peer reviewer comments	7
Extravascular factor IX after gene therapy in hemophilia B, does it matter?	7
A novel mechanism underlying allosteric regulation of ADAMTS-13 revealed by hydrogen−deuterium exchange plus mass spectrometry	7
The role of factor V in trauma-induced coagulopathy: an observational and experimental study	7
Joint effect of ischemic stroke and obesity on the risk of venous thromboembolism: the Tromsø Study	7
PB0812 The Importance of the Amino-Acid Residue at Position 2561 in the C4-Domain of von Willebrand Factor	7
Recanalization and outcomes after cerebral venous thrombosis: a systematic review and meta-analysis	7
Management of cancer‐associated thrombosis with thrombocytopenia: Impact of the ISTH guidance statement	7
PB0763 Sudden Bilateral Deafness Revealing Anti Phospholipid Syndrome	7
PB1264 Thrombin Generation Assay as a Treatment Tracking Tool in Hemophilia Patients: a Retrospective Cohort Study	7
PB0574 Severe Bleeding in an Acquired Factor XIII Deficiency in an Otherwise Healthy Patient	7
PB0505 Outcomes of Patients with Pulmonary Embolism Admitted to the Intensive Care Unit	7
Recombinant factor VIIa: new insights into the mechanism of action through product innovation	7
131 Evaluation of Hemoglobin Monitoring Frequency in Patients on Anticoagulation Therapy	7
Heavy or healthy? Assessing menstrual bleeding and bleeding tendency in Dutch adolescents	7
	7
Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)	7
PB0595 The Profile of Contact Activation System Proteins in Human Abdominal Aortic Aneurysm Plasma-and Tissue Samples	7
PB0699 Idarucizumab for Dabigatran Reversal: A Systematic Review and Meta-Analysis of Indications and Outcomes	7
PB1153 Shortening of APTT when Heparin Neutralising Calcium Solution Replaces Calcium Alone is Highly Specific for the Presence of Heparin	7
Corrigendum to ‘Hand grip strength and risk of incident venous thromboembolism: The Tromsø study’	7
Machine learning analysis of bleeding status in venous thromboembolism patients	7
PB0257 Adequate Menstrual Suppression in Adolescents with Bleeding Disorders Often Requires Multiple Treatment Changes: Five-Year Experience of a Large Multidisciplinary Clinic	7
PB1491 Prevention of Venous Thromboembolism after Thermal Methods of Treatment of Lower Extremity Varicose Vein Disease	7
Enhanced thrombin and plasmin generation profiles in alpha-2-antiplasmin–deficient patients: Data from the Rare Bleeding disorders in the Netherlands study	7
Comparing survival with vitamin K antagonists, low molecular weight heparin and direct oral anticoagulants in patients with cancer- a systematic review and meta-analysis	7
Hypocoagulability in severe yellow fever infection is associated with bleeding: results from a cohort study	7
Predictors of diagnostic delays and loss to follow-up in women with von Willebrand disease: a single-center retrospective cohort study	7
Red blood cell-derived transglutaminase-2 influences thrombus formation	7
PB1388 Sticky Platelet Syndrome: Clinical Experience from a Tertiary Center	7
PB0910 Evaluation of the Clot Formation Tranfusing Fresh, Cold and Frozen Platelets. Advantages for the Military Environment	7
OC 50.2 Low Dose FVIII Injections as a Potential Treatment to Prevent Inhibitor Development in Hemophilia a - an in Vivo Study	7
Cross-reacting antiporcine factor VIII inhibitors in patients with acquired hemophilia A	7
Management of congenital dysfibrinogenemia in pregnancy: A challenging patient case	7